The role of heart surgery in the treatment of cardiovascular diseases

According to the latest WHO statistics, in 2023, about 520 million people in the world will suffer from cardiovascular disease, and of these, 19 million people will die every year, while cardiovascular patients still have the first rank of deaths in the world (more than 30% of all deaths).

Although lifestyle prevents these deaths, treatments such as: medicine, minimally invasive, and surgical treatment are also very effective in reducing human casualties.

One of the prevalent methods of treating cardiovascular diseases is heart surgery. This method is for treat heart vascular diseases, valvular diseases, and congenital diseases.

Every year, more than 1,100,000 patients around the world undergo various types of heart surgery, and this statistic in Iran is about 40-35 thousand operations per year.

An advanced cardiopulmonary machine and oxygenator are needed to perform heart surgery. In this surgery, blood flows from the heart through a “venous cannula” and then oxygenation (exchange of oxygen and carbon dioxide in the oxygenator), the blood returned to the body through an “arterial cannula”.

Cannulae play a significant role in connecting the patient and the cardiopulmonary machine, and their advanced technology allows heart surgery to be performed easily, reliably and without damaging blood cells. presently, the technology for making these cannulas is exclusively available to a few developed countries in the world.

Gohar Shafa company is one of the few companies in the world that have started designing and producing these strategic products since 2017 with the support of young and expert staffs. Currently, these Iranian high-quality products compete with well-known products, and according to the intended plans, its coverage will be more widespread all over the world.

Cannulas used in heart surgery in three groups:

•  “Arterial cannulas”
• “Venous cannulas”
•  “Cardioplegia Cannulas”